739 related articles for article (PubMed ID: 28787019)
21. Both microtubule-stabilizing and microtubule-destabilizing drugs inhibit hypoxia-inducible factor-1alpha accumulation and activity by disrupting microtubule function.
Escuin D; Kline ER; Giannakakou P
Cancer Res; 2005 Oct; 65(19):9021-8. PubMed ID: 16204076
[TBL] [Abstract][Full Text] [Related]
22. [Characterization of the mechanism of cross-resistance to vinca alkaloids and taxoids in the human J82 bladder tumor cell line].
Debal V; Allam N; Morjani H; Millot JM; Gourdier B; Breillout F; Manfait M
Bull Cancer; 1994 Oct; 81(10):891-3. PubMed ID: 7734773
[TBL] [Abstract][Full Text] [Related]
23. Alterations in tumor necrosis factor signaling pathways are associated with cytotoxicity and resistance to taxanes: a study in isogenic resistant tumor cells.
Sprowl JA; Reed K; Armstrong SR; Lanner C; Guo B; Kalatskaya I; Stein L; Hembruff SL; Tam A; Parissenti AM
Breast Cancer Res; 2012 Jan; 14(1):R2. PubMed ID: 22225778
[TBL] [Abstract][Full Text] [Related]
24. Effect of Vinca Alkaloids on the Expression Levels of microRNAs Targeting Apoptosis-related Genes in Breast Cancer Cell Lines.
Mavrogiannis AV; Kokkinopoulou I; Kontos CK; Sideris DC
Curr Pharm Biotechnol; 2018; 19(13):1076-1086. PubMed ID: 30417784
[TBL] [Abstract][Full Text] [Related]
25. Taxanes, microtubules and chemoresistant breast cancer.
McGrogan BT; Gilmartin B; Carney DN; McCann A
Biochim Biophys Acta; 2008 Apr; 1785(2):96-132. PubMed ID: 18068131
[TBL] [Abstract][Full Text] [Related]
26. Decreased levels of baseline and drug-induced tubulin polymerisation are hallmarks of resistance to taxanes in ovarian cancer cells and are associated with epithelial-to-mesenchymal transition.
Duran GE; Wang YC; Moisan F; Francisco EB; Sikic BI
Br J Cancer; 2017 May; 116(10):1318-1328. PubMed ID: 28399108
[TBL] [Abstract][Full Text] [Related]
27. Targeting microtubules for cancer chemotherapy.
Zhou J; Giannakakou P
Curr Med Chem Anticancer Agents; 2005 Jan; 5(1):65-71. PubMed ID: 15720262
[TBL] [Abstract][Full Text] [Related]
28. [Microtubules and antineoplastic drugs].
Arioka H; Saijo N
Gan To Kagaku Ryoho; 1994 Apr; 21(5):583-90. PubMed ID: 7908790
[TBL] [Abstract][Full Text] [Related]
29. A Promising Microtubule Inhibitor Deoxypodophyllotoxin Exhibits Better Efficacy to Multidrug-Resistant Breast Cancer than Paclitaxel via Avoiding Efflux Transport.
Zang X; Wang G; Cai Q; Zheng X; Zhang J; Chen Q; Wu B; Zhu X; Hao H; Zhou F
Drug Metab Dispos; 2018 May; 46(5):542-551. PubMed ID: 29523600
[TBL] [Abstract][Full Text] [Related]
30. The novel microtubule-destabilizing drug BAL27862 binds to the colchicine site of tubulin with distinct effects on microtubule organization.
Prota AE; Danel F; Bachmann F; Bargsten K; Buey RM; Pohlmann J; Reinelt S; Lane H; Steinmetz MO
J Mol Biol; 2014 Apr; 426(8):1848-60. PubMed ID: 24530796
[TBL] [Abstract][Full Text] [Related]
31. Survivin counteracts the therapeutic effect of microtubule de-stabilizers by stabilizing tubulin polymers.
Cheung CH; Chen HH; Kuo CC; Chang CY; Coumar MS; Hsieh HP; Chang JY
Mol Cancer; 2009 Jul; 8():43. PubMed ID: 19575780
[TBL] [Abstract][Full Text] [Related]
32. Detection of pleiotropic drug resistance by the rapid immunofluorescence assay of drug effects on the cell skeleton.
Mujagić H; Mujagić Z
Oncology; 1991; 48(3):202-9. PubMed ID: 2023698
[TBL] [Abstract][Full Text] [Related]
33. Exploitation of the Androgen Receptor to Overcome Taxane Resistance in Advanced Prostate Cancer.
Martin SK; Kyprianou N
Adv Cancer Res; 2015; 127():123-58. PubMed ID: 26093899
[TBL] [Abstract][Full Text] [Related]
34. Improving the targeting of tubulin-binding agents: lessons from drug resistance studies.
Verrills NM; Kavallaris M
Curr Pharm Des; 2005; 11(13):1719-33. PubMed ID: 15892670
[TBL] [Abstract][Full Text] [Related]
35. [Antitubulin agents].
Dumontet C
Bull Cancer; 2011 Nov; 98(11):1275-85. PubMed ID: 22023745
[TBL] [Abstract][Full Text] [Related]
36. Calmodulin, activated cyclic nucleotide phosphodiesterase, microtubules, and vinca alkaloids.
Watanabe K; West WL
Fed Proc; 1982 May; 41(7):2292-9. PubMed ID: 6122611
[TBL] [Abstract][Full Text] [Related]
37. Microtubule inhibitors: Differentiating tubulin-inhibiting agents based on mechanisms of action, clinical activity, and resistance.
Perez EA
Mol Cancer Ther; 2009 Aug; 8(8):2086-95. PubMed ID: 19671735
[TBL] [Abstract][Full Text] [Related]
38. The stepwise evolution of the exome during acquisition of docetaxel resistance in breast cancer cells.
Hansen SN; Ehlers NS; Zhu S; Thomsen MB; Nielsen RL; Liu D; Wang G; Hou Y; Zhang X; Xu X; Bolund L; Yang H; Wang J; Moreira J; Ditzel HJ; Brünner N; Schrohl AS; Stenvang J; Gupta R
BMC Genomics; 2016 Jun; 17():442. PubMed ID: 27277198
[TBL] [Abstract][Full Text] [Related]
39. Mechanism of inhibition of cell proliferation by Vinca alkaloids.
Jordan MA; Thrower D; Wilson L
Cancer Res; 1991 Apr; 51(8):2212-22. PubMed ID: 2009540
[TBL] [Abstract][Full Text] [Related]
40. Gatorbulin-1, a distinct cyclodepsipeptide chemotype, targets a seventh tubulin pharmacological site.
Matthew S; Chen QY; Ratnayake R; Fermaintt CS; Lucena-Agell D; Bonato F; Prota AE; Lim ST; Wang X; Díaz JF; Risinger AL; Paul VJ; Oliva MÁ; Luesch H
Proc Natl Acad Sci U S A; 2021 Mar; 118(9):. PubMed ID: 33619102
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
